Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi‐Center Real‐Life Study
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ABSTRACT In elderly patients with high‐risk classic Hodgkin lymphoma (c‐HL), we evaluated the impact of a new modality treatment without bleomycin, that is, liposomal doxorubicin (NPLD)‐based regimen plus consolidation radiotherapy of residual nodal masses (RNMs), on overall survival (OS) and progression free survival (PFS). In this retrospective study (2013–2023) conducted in tertiary hospitals in the bay of Naples (Italy), 50 older adults (median age, 69 years; range, 60–89) with advanced stage c‐HL received frontline treatment with MVD ± irradiation. MVD consisted of 25 mg/m 2 of NPLD along with standard Vinblastine and Dacarbazine for a total of 6 cycles (twelve iv administrations, every 2 weeks) followed by radiation of RNMs with size ≥ 2.5 cm at computed tomography. Patients underwent MVD with a median dose intensity of 92%. At 2‐deoxy‐2[F‐18] fluoro‐D‐glucose positron emission tomography (FDG‐PET), 90% of patients (45/50 patients; one failed to perform final FDG‐PET due to early death) reached complete responses. Altogether, 17 patients (34%) received consolidation radiotherapy of RNMs with Deauville score ≥ 3. At 5‐year median follow‐up, the OS and PFS of the entire population were 87.5% (95% confidence interval [CI], 78.7–97.4) and 81.6% (95% CI, 71.4–93.2), respectively. Eleven patients (22%) experienced grade ≥ 3 adverse events, and 4 of them required hospitalization. Our data suggest that in older adults with high‐risk c‐HL NPLD‐driven strategy (without bleomycin) plus consolidation radiotherapy (if needed) may be a promising up‐front option, to test in phase II clinical trials for improving survival incidence.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi‐Center Real‐Life Study
- Date Crossref
- 01/11/2024
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Federico II University Hospital pays non établi dans la noticeÉtablissement de santé
-
Ospedale Antonio Cardarelli pays non établi dans la noticeÉtablissement de santé
-
Fatebenefratelli Hospital pays non établi dans la noticeÉtablissement de santé
-
Department of Clinical Medicine and Surgery Federico II University Medical School Naples Italy Department of Clinical Medicine and Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Department of Public Health Federico II University Medical School Naples Naples Italy pays non établi dans la noticeUniversité ou école supérieure
-
Department of Advanced Biomedical Sciences Federico II University Medical School Naples Italy pays non établi dans la noticeUniversité ou école supérieure
-
Departments of Translational Medical Sciences Federico II University Medical School Naples Italy pays non établi dans la noticeUniversité ou école supérieure
-
Hematology Unit Antonio Cardarelli Hospital of National Importance Naples Italy Hematology Unit pays non établi dans la noticeÉtablissement de santé
Federico II University Hospital, Ospedale Antonio Cardarelli et Fatebenefratelli Hospital, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.